Preview

Pharm

Satisfactory Essays
Open Document
Open Document
508 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Pharm
Pharmagen Pharmaceutical Development Funding

Overview of the case:
Pharmagen, a pharmaceutical company entered into a funding agreement with an unrelated third-party private equity investor (PEI).
As part of the Agreement, the company will receive up to a total of $500 million from the PEI for R&D costs incurred by the development of a potential new drug X only.
If at any time the project is scrapped the amount received by Pharmagen is non-refundable.
Pharmagen retains all the intellectual property rights to X. The investor will receive royalty payments of new drug X and an existing commercialized drug.

Problem:
How to account for the funding of the R&D and royalty payments

R&D cost – first way:
ASC 730-20 is applicable
Based on the fact given in the case, none of the four conditions under ASC 730-20-25-6 relate to the Pharmagen. Therefore, we cannot make a decision if it is liability.
However, under ASC 730-20-25-8, the repayment of funds provided must depend only on the result of the R&D having future economic benefit.
Since the PEI has a contingency relating to the sales of an existing commercial drug, the repayment is not solely reliant on the development of drug X. Therefore, Pharmagen is not transferring all financial risk to PEI
As a result, the funding must be recorded as a liability.
Following the guidance provide by ASC 730-20 is the best option for the case because of the high risk of potential failure for the product.

R&D cost – second way:
ASC 470-10-25 is applicable
This standard applies to an entity which receives a specified percent of the revenue related to a particular product line.
Based on the ASC 470-10-25-2, if one factor is met, the proceeds are considered debt. The first factor is whether or not the transaction takes the likeness of a sale.
In the case, since PEI is receiving a percentage of an existing drug which indicates that it is a sale. As a result, the proceeds are considered debt.
However, due to the

You May Also Find These Documents Helpful

  • Satisfactory Essays

    Trueblood Case 09 2

    • 804 Words
    • 2 Pages

    The agreement states Pharmagen will receive up to $500 million funding for R&D costs as they are incurred solely for the research efforts of a potential new drug “X”…

    • 804 Words
    • 2 Pages
    Satisfactory Essays
  • Satisfactory Essays

    Scm421merckcasereport 2

    • 790 Words
    • 3 Pages

    The initial decision Merck must make is whether to purchase the drug rights of the KL-798 product. It will initially cost $30 million up front and an additional $5 million to complete phase one. Disregarding Mr. Merck’s philosophy, the program suggests to not invest in drug rights due to an overall loss of $260,000.…

    • 790 Words
    • 3 Pages
    Satisfactory Essays
  • Powerful Essays

    Direct Drugs Inc. (Direct) has created a plan for the acquisition of SolvGen Inc. (SolvGen), which is a publicly owned company. Direct has engaged an audit team to review agreement and procedures dealing with two separate material agreements. The first agreement is a research and development agreement and the second is a licensing and distribution agreement. The contract states that SolvGen entered into a five year research and development agreement with Careway Pharma Inc. on January 1, 2010. The agreement states that SolvGen will use its best efforts to develop a proprietary instrument system. They are expected to be ready for launch in the near future. SolvGen and Careway also entered in an agreement for a five year license and distribution. This agreement was entered in on January 1, 2010 as well. The terms of the research and development agreement state that SolvGen holds all intellectual rights that correspond with the research and development of the contract. Also with this agreement SolvGen is entitled to nonrefundable milestone payments from Careway and they are as follows:…

    • 1100 Words
    • 5 Pages
    Powerful Essays
  • Good Essays

    Pharmagen

    • 508 Words
    • 2 Pages

    2. The funding can be seen as a package deal for both X and Y and is said to be for sale of royalty rights of Y and also for future R&D for X. Royalties of Y can be seen as an incentive. Royalties for Y might be expected to receive royalties and conditions are probable because Y is commercialized already as per ASC 730-20-25-5. This is separate from R&D of product X. The entity “essentially completed the project before entering into the arrangement.” (ASC 730-20-25-6). Funding, when it comes to Y, can be seen as an interest in future revenue. It will be a deferred income for the entity and will be capitalized and proportionally used for the defined period.(ASC 470-10-25-1&2) as royalties are paid to the investor. Incremental funding is determined by the progress of product X and that progress is not measured in the case. It could be by development stage, increased marketability,…

    • 508 Words
    • 2 Pages
    Good Essays
  • Good Essays

    Pharmagen Case Summary

    • 653 Words
    • 3 Pages

    In this situation I would argue that ASC 730-20 is applicable. Pharmagen is entering into an agreement with PEI (investors) on a contractual basis to provide services and an option to acquire the results of the R&D (FASB 68). Pharmagen retains all ownership rights to the development of X. It also states that in R&D arrangements the entity (in this case Pharmagen) usually has an option to either purchase the partnership’s interest (PEI) or to obtain the exclusive rights to the entire results in return for a lump sum payment or royalty payments to the partnership (in this case PEI). This clearly fits into Pharmagen’s case since PEI is entitled to receive future royalties from Pharmagen in return for contributions (funds) for the development of X.…

    • 653 Words
    • 3 Pages
    Good Essays
  • Satisfactory Essays

    Drugking

    • 951 Words
    • 3 Pages

    Drug King has two financial assets, an investment in Series A and Series B preferred stock of TIp-Top that it will transfer to InsureAll. Series A stock is traded publically and has a call option written by InsureAll which allows the repurchase of the stock two years after the transfer date with a fixed exercise date. The Series B preferrd stock, which is not publically traded, will be transferred to InsureAll with a call option attached to the stock allowing DrugKing to repurchase the stock from whomever owns it as long as the purchase is completed within two years of the transfer date and like the Series A preferred stock it has a fixed exercise price. An outside source has also concluded that both "transfers isolate the transferred asset…beyond the reach of DrugKing and it creditors, even in bankruptcy or other receivership."…

    • 951 Words
    • 3 Pages
    Satisfactory Essays
  • Good Essays

    MGMT 108 Case 2

    • 1251 Words
    • 1 Page

    interest. Therefore, under Article 9 of the Uniform Commercial Code, buyers in the ordinary course of…

    • 1251 Words
    • 1 Page
    Good Essays
  • Satisfactory Essays

    Paper

    • 390 Words
    • 2 Pages

    the process and license the process to large pharmaceutical companies for their use in medication…

    • 390 Words
    • 2 Pages
    Satisfactory Essays
  • Satisfactory Essays

    Sirtris

    • 574 Words
    • 3 Pages

    * • Partnership with Pharma. As is almost always the case in biotech, the team was in…

    • 574 Words
    • 3 Pages
    Satisfactory Essays
  • Better Essays

    Cephalon case

    • 804 Words
    • 2 Pages

    1. If Myotrophin is approved by the FDA, would you recommend that Cephalon follows a strategy of making an immediate onetime payment to purchase all of the rights to this drug rather than making a stream of payments under the milestone payment/interim license/purchase option agreement that was in place? Explain your reasoning.…

    • 804 Words
    • 2 Pages
    Better Essays
  • Better Essays

    Merck Kl798 Case

    • 920 Words
    • 4 Pages

    Merck & Company has been presented with an opportunity to invest $30 million for the purchasing rights of an obesity and high cholesterol lowering drug, KL-798 from Kappa Labs. Based on the expected probabilities of success through each product-development phase for this new drug, as well as the costs involved, the net present value of the project is -$1.16 million and is therefore recommended that Merck passes on the investment. Sensitivity analysis also show that adjusting the probabilities of successfully passing each approval process to more realistic expectations has a drastically negative affect on the project NPV.…

    • 920 Words
    • 4 Pages
    Better Essays
  • Powerful Essays

    Case Study Pti

    • 2533 Words
    • 11 Pages

    Glickman’s central concern seems to be how would PTI secure the second tranche of investment from the investors in their research for the development of a new oral therapy male sexual dysfunction. With accelerating cash requirements to be able to complete the studies planned, PTI is under pressure to show results in order to avail the second phase of capital. However, a deeper analysis brings forth larger strategic issues that PTI needs to decide upon in order to reach the next level of their work. Due to the proprietary technology they own it is imperative that they select a partner for co-development of the final product in a short time frame so that the product can be brought to the market while the market is still profitable. Also, the short time frame to accomplish the alliance as well as complete the “technologically sophisticated and time consuming studies” (Herbert, 2004) to test the compatibility of the Factor X compounds with PTI’s technology is also due to the milestones PTI needs to achieve in order to avail the second round of funding. There is also a question on what kind of alliance should be the most effective in this situation. Not only are in-licensing and out-licensing being considered but since, the…

    • 2533 Words
    • 11 Pages
    Powerful Essays
  • Good Essays

    Bazerman (pg., 151) tells us that major pharmaceutical companies develop and market cancer drugs. However, they sell the drug because it is not profitable because of the high cost and small market. A major pharmaceutical company meets with a smaller unknown company and agrees to sell it to them with full knowledge that they are going to increase the cost of the pill regardless if people depend on it for survival. This unethical move will make it harder for patients to obtain the drug because of the inflated…

    • 539 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Budget Airline

    • 2277 Words
    • 7 Pages

    The enforcement of patent law in the pharmaceutical industry is particularly important. A recent report by Ernst and Young LLP found that for every drug that is able to pass the entire test and acquire the certification to launch to the market, on average, it costs $500 million.…

    • 2277 Words
    • 7 Pages
    Good Essays
  • Good Essays

    Ythgjnm

    • 414 Words
    • 2 Pages

    its schizophrenia drug , Zyprexa allegedly has on the people who take it . The liability that exists in this case arises from a tortuous act if it is reasonably shown in court that there is a connection between the increased risk to diabetes and other side-effects and the prescription of the drug Zyprexa…

    • 414 Words
    • 2 Pages
    Good Essays